Yabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication

Stock News

Aug 25

Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.

SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1112421026"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1112421026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1112421026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 15:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112421026","market":"sh","top_or_hot":-1,"title":"Yabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication","media":"Stock News","content":"<p>Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.</p>\n<p>SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Yabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nYabao Pharmaceutical Group (600351.SH): SY-005 Project Receives Clinical Trial Approval for New Indication\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-25 15:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.</p>\n<p>SY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0201","symbol_name":"可转债","start_time":0,"source_url":"","article_id":"1112421026","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112421026","pubTimestamp":1756107385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600351":"亚宝药业","BK0201":"可转债","BK4563":"昨日强势股","BK0077":"质押式回购","BK4503":"景林资产持仓","BK0028":"国家队","BK0239":"医药制造","BK4077":"互动媒体与服务","SY":"新氧","BK0096":"民营医院"},"translate_title":"亚宝药业集团（600351.SH）：SY-005项目获新适应症临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600351":1,"SY":1},"content_text":"Yabao Pharmaceutical Group Co.,Ltd. (600351.SH) announced that its controlling subsidiary Suzhou Yabao Pharmaceutical R&D Co., Ltd. has received the \"Clinical Trial Approval Notice\" issued by the National Medical Products Administration for an additional indication of SY-005 injection. The approval permits clinical trials of SY-005 injection for treating post-operative neurological dysfunction following brain glioma surgery.\nSY-005 is an innovative recombinant protein that received clinical trial approval for sepsis treatment in November 2018. The sepsis indication is currently in Phase II clinical trials. The newly approved indication for SY-005 injection is post-operative neurological dysfunction after brain glioma surgery.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}